Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP & Chief Medical Officer | February 22, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date February 22, 2024 · Filed February 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,111 |
Reported balance
After 2024-02-22 transaction · row 1
1 source rowRow 1 · 2024-02-22 · Sale · Disposed 14,568 · Balance 250,111 F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2020 Filed Nov 16, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-20-058488 · doc4.xml · derivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,333 Underlying: Common Stock · 20,000 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 20,000 | $0.86 | $17,100.00 |
DisclosureSEC source: 0001209191-20-058488 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 5, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 5,000 | $1.53 | $7,650.00 |
DisclosureSEC source: 0001209191-20-057160 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 22:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,315 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-20-055604 · doc4.xml · derivative · entry 8 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,129 Underlying: Common Stock · 2,315 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 22:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,315 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-055604 · doc4.xml · derivative · entry 7 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,612 Underlying: Common Stock · 2,315 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 22:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,870 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-055604 · doc4.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,591 Underlying: Common Stock · 7,870 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 22:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $35.59 | $177,951.50 |
DisclosureSEC source: 0001209191-20-055604 · doc4.xml · nonDerivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 22:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $35.42 | $265,656.75 |
DisclosureSEC source: 0001209191-20-055604 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 22:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,315 | $5.18 | $11,980.13 |
DisclosureSEC source: 0001209191-20-055604 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 22:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,315 | $1.58 | $3,646.13 |
DisclosureSEC source: 0001209191-20-055604 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2020 Filed Oct 22, 2020 22:15 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 7,870 | $1.53 | $12,041.10 |
DisclosureSEC source: 0001209191-20-055604 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2020 Filed Nov 5, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-057160 · doc4.xml · derivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,591 Underlying: Common Stock · 5,000 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 21, 2020 Filed Nov 5, 2020 22:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $31.44 | $157,209.00 |
DisclosureSEC source: 0001209191-20-057160 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,315 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-054284 · doc4.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,927 Underlying: Common Stock · 2,315 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,185 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-054284 · doc4.xml · derivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,461 Underlying: Common Stock · 10,185 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $41.73 | $208,629.00 |
DisclosureSEC source: 0001209191-20-054284 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $41.76 | $313,166.25 |
DisclosureSEC source: 0001209191-20-054284 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,315 | $1.58 | $3,646.13 |
DisclosureSEC source: 0001209191-20-054284 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2020 Filed Oct 8, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,185 | $1.53 | $15,583.05 |
DisclosureSEC source: 0001209191-20-054284 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,315 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-20-051170 · doc4.xml · derivative · entry 8 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,444 Underlying: Common Stock · 2,315 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 465 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001209191-20-051170 · doc4.xml · derivative · entry 7 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,646 Underlying: Common Stock · 465 shares Expires 2028-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,720 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-051170 · doc4.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,242 Underlying: Common Stock · 9,720 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $31.92 | $159,591.00 |
DisclosureSEC source: 0001209191-20-051170 · doc4.xml · nonDerivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $31.88 | $239,103.00 |
DisclosureSEC source: 0001209191-20-051170 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,315 | $5.18 | $11,980.13 |
DisclosureSEC source: 0001209191-20-051170 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 465 | $1.53 | $711.45 |
DisclosureSEC source: 0001209191-20-051170 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 9,720 | $1.58 | $15,309.00 |
DisclosureSEC source: 0001209191-20-051170 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-049397 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,962 Underlying: Common Stock · 12,500 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $32.91 | $164,537.00 |
DisclosureSEC source: 0001209191-20-049397 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $32.88 | $246,621.75 |
DisclosureSEC source: 0001209191-20-049397 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| September 02, 2020 Filed Sep 3, 2020 20:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 12,500 | $1.58 | $19,687.50 |
DisclosureSEC source: 0001209191-20-049397 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-20-047942 · doc4.xml · derivative · entry 8 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,333 Underlying: Common Stock · 14,000 shares Expires 2027-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the 111,110 shares originally subject to the stock option vested and became exercisable on December 14, 2017, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,315 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-20-047942 · doc4.xml · derivative · entry 7 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,759 Underlying: Common Stock · 2,315 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. F4 · balance_after: The total number of shares remaining under this stock option has been adjusted by 50 shares to correct a typographical error that occurred in the reporting person's Form 4 filed July 2, 2020. The total number of shares remaining under this stock option following the transaction reported on July 2, 2020 was underreported by 50 shares. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,185 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-047942 · doc4.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,462 Underlying: Common Stock · 10,185 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $50.94 | $382,047.75 |
DisclosureSEC source: 0001209191-20-047942 · doc4.xml · nonDerivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $50.96 | $254,807.50 |
DisclosureSEC source: 0001209191-20-047942 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 14,000 | $0.86 | $11,970.00 |
DisclosureSEC source: 0001209191-20-047942 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,315 | $5.18 | $11,980.13 |
DisclosureSEC source: 0001209191-20-047942 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:39 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,185 | $1.58 | $16,041.38 |
DisclosureSEC source: 0001209191-20-047942 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:07 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-045688 · doc4.xml · derivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,647 Underlying: Common Stock · 12,500 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:07 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $50.89 | $381,695.25 |
DisclosureSEC source: 0001209191-20-045688 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:07 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $50.91 | $254,526.50 |
DisclosureSEC source: 0001209191-20-045688 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:07 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 12,500 | $1.58 | $19,687.50 |
DisclosureSEC source: 0001209191-20-045688 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 7,500 | $49.52 | $371,435.25 |
DisclosureSEC source: 0001209191-20-042652 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $49.54 | $247,683.00 |
DisclosureSEC source: 0001209191-20-042652 · doc4.xml · nonDerivative · entry 3 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 2,314 | $5.18 | $11,974.95 |
DisclosureSEC source: 0001209191-20-042652 · doc4.xml · nonDerivative · entry 2 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2020 Filed Jul 16, 2020 21:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionCommon Stock | 10,186 | $1.58 | $16,042.95 |
DisclosureSEC source: 0001209191-20-042652 · doc4.xml · nonDerivative · entry 1 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,722 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001209191-20-040662 · doc4.xml · derivative · entry 6 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,338 Underlying: Common Stock · 9,722 shares Expires 2029-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on March 11, 2020, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,778 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-040662 · doc4.xml · derivative · entry 5 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,333 Underlying: Common Stock · 2,778 shares Expires 2028-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:42 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 5,000 | $37.77 | $188,840.50 |
DisclosureSEC source: 0001209191-20-040662 · doc4.xml · nonDerivative · entry 4 Pang Phillip · CIK 0001787370 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,777 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.